MEDLINE INDUSTRIES LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +15.9%

  £48,554,872 → £56,273,786

• Cash

  -35.5%

  £6,699,956 → £4,324,104

  lowest in 4 filed years

• Net assets

  +12.1%

  £6,995,186 → £7,839,154

• Employees

  +8.9%

  45 → 49

  highest in 4 filed years

• Operating profit

  +15.5%

  £900,456 → £1,040,198

• Profit before tax

  +12.8%

  £1,011,734 → £1,140,876

• Wages

  +1.7%

  £4,000,196 → £4,070,137

  highest in 4 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. MEDLINE INDUSTRIES LIMITED 2011-05-10 → present
2. CAREFUSION U.K. 223 LIMITED 2009-09-01 → 2011-05-10
3. CARDINAL HEALTH U.K. 223 LIMITED 2003-06-02 → 2009-09-01
4. ALLEGIANCE HEALTHCARE LIMITED 1996-10-10 → 2003-06-02
5. INTERCEDE 1193 LIMITED 1996-08-15 → 1996-10-10

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The company operates within both the public and private healthcare systems and despite significant pricing pressures, demand for these products remains high. The business model is such that the company is intrinsically linked to the wider Medline group of companies and therefore the company's ability to continue to be a going concern is linked to the wider Medline group. Cash flow forecasts are prepared at a consolidated Medline group basis, using planning inputs from each of the individual entities within the group. The forecast is then subject to review, challenge and sign off at a group level. Due to the company's cash flows being linked to the performance of the wider Medline group and the cash flows being prepared on a consolidated basis, the Directors have received a letter of support from the Company's ultimate parent company, Medline Holdings, LP. The letter confirms ongoing financial support until 30 November 2026. The Directors have satisfied themselves that Medline Holdings, LP can provide this support to the Company should it be required following enquiries with the parent company directors and review of the Medline Holdings, LP financial position. As a result the financial statements are prepared on a going concern basis.”

Significant events

• “Sales in 2024 are higher than in 2023, aligned with our focus of organic growth. In the coming years the focus will be on acquisitions, expecting an increase in non-organic sales growth. Due to the growth of the Medline Group, a growth of employees is expected for 2025 and the years after. The legal structure of the company is not expected to change.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.